![Stack of newspapers on a computer keyboard.](https://www.ppd.com/wp-content/uploads/2023/03/newspapers-keyboard_1447105652-1280x600.jpg)
In the News
Breaking barriers: Strategic use of FSP models to expand trials into non-footprint countries
Lisa Beckel discusses how leveraging functional service provider models can enhance global clinical trial reach and inclusion.
![Contract Pharma](https://www.ppd.com/wp-content/uploads/2019/12/Contract-Pharma-e1578492947862.jpg)
From Hematologic to Autoimmune Disease – The CAR-T Therapy Second Revolution
CAR-T therapy has entered a new era with its potential application in autoimmune, metabolic and other chronic conditions. Davide Garrisi and Kim Watanabe explore how CAR-T therapy is poised to make a significant impact on patients' lives.
![BioSpectrum Asia logo](https://www.ppd.com/wp-content/uploads/2024/05/BioSpectrumAsia-logo.png)
Five critical elements for maximizing functional service partnerships
As organizations look more to functional service partnership models to outsource specific functions of clinical trials, the authors discuss five keys to successfully implementing those relationships.
![Drug Discovery & Development Logo](https://www.ppd.com/wp-content/uploads/2023/04/DDD_Image-1.jpg)
Beat the clock: How an FSP model can optimize a follow-the-sun approach in clinical development functions
Our experts discuss how a follow-the-sun model delivered in a flexible functional service provider outsourcing model is being used to respond to more challenging timelines.
![pharmaceutical outsourcing logo](https://www.ppd.com/wp-content/uploads/2019/12/pharmaceutical-outsourcing.jpg)
How much does a clinical research associate impact a company’s carbon footprint? More than you might think!
Michael Cohen discusses the need to better understand our respective carbon footprints and develop solutions to reduce the environmental impact of clinical trials.
![Drug Discovery & Development Logo](https://www.ppd.com/wp-content/uploads/2023/04/DDD_Image-1.jpg)
What’s APAC’s recipe of success in clinical trials market?
Ding Ming talks about the ongoing efforts foster an environment that is more conducive to clinical trials.
![BioSpectrum Asia logo](https://www.ppd.com/wp-content/uploads/2024/05/BioSpectrumAsia-logo.png)
Real-world evidence key to navigating new policy changes
Evidera’s Ariel Berger and Almudena Olid Gonzalez discuss the expanding role of real-world evidence in drug development.
![Drug Discovery & Development Logo](https://www.ppd.com/wp-content/uploads/2023/04/DDD_Image-1.jpg)
Unleashing their potential: the evolving landscape of DHTs
Jill Sommerville, Lauren Flood and Matthew Ryan outline key considerations in deploying fit-for-purpose digital health technologies in drug development.
![AppliedClinTrials logo](https://www.ppd.com/wp-content/uploads/2023/04/AppliedClinTrials-3.png)
Cracking the talent shortfall: strategies for delivering the right talent with an FSP model
Jason Tate lays out multiple approaches to weathering clinical research workforce constraints through the use of FSPs.
![CenterWatch Logo](https://www.ppd.com/wp-content/uploads/2024/04/CenterWatch-Logo.png)